Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gimistotug combinations in anti-PD-(L)1 pretreated NSCLC
NCT06029127Phase 2Completed
- Sponsor
- BeiGene
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of gimistotug in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Oct 2023; status: completed.
02
Drugs
gimistotug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06029127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029127.